Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?

Published:2019-12 Issue:3 Volume: Page:1-2
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Leonetti Alessandro¹,Tiseo Marcello¹,Rolfo Christian¹,Van Der Steen Nele¹,Peters Godefridus J.¹,Giovannetti Elisa¹

Affiliation:

1. Alessandro Leonetti, MD, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands, and University Hospital of Parma, Parma, Italy; Marcello Tiseo, MD, PhD, University Hospital of Parma and University of Parma, Parma, Italy; Christian Rolfo, MD, PhD, MBA, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD; Nele Van Der Steen, PhD, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands, and Center...

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.19.00180

Reference10 articles.

1. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC

2. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

3. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

4. Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP